Top

Breast Cancer Research and Treatment

Published in:

01-02-2010 | Letter to the Editor

Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China

Authors: A-Yong Cao, Zhen Hu, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Excerpt

To the editor …

Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11(2):103–105CrossRefPubMed

Li WF, Hu Z, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109CrossRefPubMed

Cao AY, Jin W, Shi PC et al (2009) Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population. Breast Cancer Res Treat. doi:10.1007/s10549-009-0349-6

Cao AY, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457–462CrossRefPubMed

Cao AY, Huang J, Hu Z et al (2009) Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 115:51–55CrossRefPubMed

Song CG, Hu Z, Yuan WT et al (2006) CHEK2 c. 1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23:443–445PubMed

Domchek SM, Weber BL (2006) Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25:5825–5831CrossRefPubMed

American Society of Clinical Oncology (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406CrossRef

Wang SM (2007) Concerns on diagnosis and treatment of breast cancer in China. Chin Med J (Engl) 120:1741–1742

10.

Harris M, Winship I, Spriggs M (2007) Controversies and ethical issues in cancer-genetics clinics. Lancet Oncol 6:301–310CrossRef

Title: Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China
Authors: A-Yong Cao
Zhen Hu
Zhi-Ming Shao
Publication date: 01-02-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0598-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Additive effects of genetic variations of xenobiotic detoxification enzymes and DNA repair gene XRCC1 on the susceptibility to breast cancer

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004

Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens

Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer